Development of targeted therapy for squamous cell carcinomas of the head and neck

Expert Review of Anticancer Therapy

Volumn 11, Issue 3, 2011, Pages 373-386

  Burgos Tiburcio, Alberto ^a   Santos, Edgardo S ^a   Arango, Belisario A ^b   Raez, Luis E ^a,c  

^a UNIVERSITY OF MIAMI   (United States)

^b HENRY FORD HOSPITAL   (United States)

^c UNIVERSITY OF MIAMI MILLER SCHOOL OF MEDICINE   (United States)

Author keywords

bevacizumab; cetuximab; erlotinib; gefitinib; head and neck squamous cell carcinoma; human papilloma virus; pemetrexed; targeted therapy

Indexed keywords

AMG 479; ANTINEOPLASTIC AGENT; BEVACIZUMAB; BORTEZOMIB; CAPECITABINE; CARBOPLATIN; CEDIRANIB; CELECOXIB; CETUXIMAB; CISPLATIN; CIXUTUMUMAB; CONTUSUGENE LADENOVEC; DOCETAXEL; EPIDERMAL GROWTH FACTOR RECEPTOR KINASE INHIBITOR; ERLOTINIB; FIGITUMUMAB; FLUOROURACIL; GEFITINIB; GEMCITABINE; HYDROXYUREA; IMC A 12; IMC C 225; LAPATINIB; METHOTREXATE; OXALIPLATIN; PANITUMUMAB; PEMETREXED; PLACEBO; PLATINUM COMPLEX; SUNITINIB; UNCLASSIFIED DRUG; UNINDEXED DRUG; VASCULOTROPIN INHIBITOR;

ABNORMAL FECES; ACNE; ADVANCED CANCER; ALANINE AMINOTRANSFERASE BLOOD LEVEL; ANEMIA; ANOREXIA; ANTINEOPLASTIC ACTIVITY; ASPARTATE AMINOTRANSFERASE BLOOD LEVEL; ASTHENIA; BLEEDING; BLEEDING DISORDER; BLOOD TOXICITY; BONE MARROW SUPPRESSION; BREAST CANCER; CANCER ADJUVANT THERAPY; CANCER COMBINATION CHEMOTHERAPY; CANCER INHIBITION; CANCER RADIOTHERAPY; CANCER STAGING; CANCER SURVIVAL; CHILL; CLINICAL EFFECTIVENESS; COLORECTAL CANCER; CONTINUOUS INFUSION; DERMATITIS; DIARRHEA; DIZZINESS; DOSAGE SCHEDULE COMPARISON; DOSE RESPONSE; DRUG DOSE COMPARISON; DRUG DOSE ESCALATION; DRUG DOSE REDUCTION; DRUG EFFECT; DRUG EFFICACY; DRUG FATALITY; DRUG INDICATION; DRUG MEGADOSE; DRUG POTENCY; DRUG SAFETY; DRUG TOLERABILITY; EWING SARCOMA; FATIGUE; FEVER; FISTULA; GASTROINTESTINAL SYMPTOM; GENE MUTATION; HEAD AND NECK CANCER; HEAD AND NECK CARCINOMA; HEMATOLOGIC MALIGNANCY; HUMAN; HYPERCALCEMIA; HYPERTENSION; HYPERTRANSAMINASEMIA; HYPOGLYCEMIA; HYPOKALEMIA; HYPOMAGNESEMIA; HYPONATREMIA; HYPOPHARYNX CARCINOMA; INJECTION SITE BLEEDING; INJECTION SITE PAIN; KIDNEY CARCINOMA; LARYNGECTOMY; LARYNX CARCINOMA; LEUKOPENIA; LOADING DRUG DOSE; LOW DRUG DOSE; LUNG NON SMALL CELL CANCER; MALIGNANT NEOPLASTIC DISEASE; METASTASIS; MOLECULARLY TARGETED THERAPY; MOUTH CARCINOMA; MUCOSA INFLAMMATION; MULTIPLE CYCLE TREATMENT; MULTIPLE MYELOMA; NAUSEA; NEUROENDOCRINE TUMOR; NEUTROPENIA; NONHUMAN; PATIENT COMPLIANCE; PROGNOSIS; PROSTATE CANCER; PROTEIN EXPRESSION; PROTEINURIA; PRURITUS; PSORIASIS; RASH; RECURRENT CANCER; REVIEW; SEPSIS; SIDE EFFECT; SIGNAL TRANSDUCTION; SINGLE DRUG DOSE; SKIN TOXICITY; SKIN ULCER; SOLID TUMOR; SQUAMOUS CELL CARCINOMA; STOMATITIS; THROMBOCYTOPENIA; THROMBOSIS; TISSUE NECROSIS; TRACHEOESOPHAGEAL FISTULA; TREATMENT DURATION; TUMOR BLEEDING; TUMOR LOCALIZATION; ULCER; UNSPECIFIED SIDE EFFECT; VIRAL GENE DELIVERY SYSTEM; VOMITING;

ANTINEOPLASTIC AGENTS; CARCINOMA, SQUAMOUS CELL; COMBINED MODALITY THERAPY; HEAD AND NECK NEOPLASMS; HUMANS; INSULIN-LIKE GROWTH FACTOR I; NEOPLASM METASTASIS; NF-KAPPA B; PROTEASOME ENDOPEPTIDASE COMPLEX; RECURRENCE; TAXOIDS; VASCULAR ENDOTHELIAL GROWTH FACTOR A;

EID: 79952961101     PISSN: 14737140     EISSN: 17448328     Source Type: Journal    
DOI: 10.1586/era.10.193     Document Type: Review

References (103)

1. Jemal A, Siegel R, Ward E, et al. Cancer statistics, 2009. CA Cancer J. Clin. 59, 225-249 (2009)
2. Mendelsohn J, Baselga J. Status of epidermal growth factor receptor antagonists in the biology and treatment of cancer. J. Clin. Oncol. 21(14), 2787-2799 (2003) (Pubitemid 46606324)
3. Salomon DS, Brandt R, Ciardiello F, Normanno N. Epidermal growth factor-related peptides and their receptors in human malignancies. Crit. Rev. Oncol. Hematol. 19(3), 183-232 (1995)
4. Citri A, Yarden Y. EGF-ErbB signaling: towards the systems level. Nat. Rev. Mol. Biol. 7(7), 505-516 (2006) (Pubitemid 44036456)
5. Hynes NE, Lane HA. ErbB receptors and cancer: the complexity of targeted inhibitors. Nat. Rev. Cancer 5(5), 341-354 (2005) (Pubitemid 40637826)
6. Normanno N, Bianco C, De Luca A, Maiello MR, Salomon DS. Target-based agents against ErbB receptors and their ligands: a novel approach to cancer treatment. Endocr. Relat. Cancer 10(1), 1-21 (2003) (Pubitemid 36457237)
7. Li S, Schmitz KR, Jeffrey PD, Wiltzius JJ, Kussie P, Ferguson KM. Structural basis for inhibition of the epidermal growth factor receptor by cetuximab. Cancer Cell 7(4), 301-311 (2005) (Pubitemid 40544648)
8. Fan Z, Lu Y, Wu X, Mendelsohn J. Antibody-induced epidermal growth factor receptor dimerization mediates inhibition of autocrine proliferation of A431 squamous carcinoma cells. J. Biol. Chem. 269(44), 27595-27602 (1994) (Pubitemid 24346592)
9. Goldstein NI, Prewett M, Zuklys K, Rockwell P, Mendelsohn J. Biological efficacy of a chimeric antibody to the epidermal growth factor in a human tumor xenograft model. Clin. Cancer Res. 1, 1311-1318 (1995)
10. Prewett M, Rockwell P, Rockwell RF, et al. The biologic effects of C225, a chimeric monoclonal antibody to the EGFR, on human prostate carcinoma. J. Immunother. Emphasis Tumor Immunol. 19(6), 419-427 (1996)
11. Mendelsohn J, Fan Z. Epidermal growth factor receptor family and chemosensitization. J. Natl Cancer Inst. 89(5), 341-343 (1997) (Pubitemid 27102599)
12. Saleh MN, Raisch KP, Stackhouse MA, et al. Combined modality therapy of A431 human epidermal cancer using anti-EGFR antibody C225 and radiation. Cancer Biother. Radiopharm. 14(6), 451-463 (1999) (Pubitemid 30029793)
13. Baselga J, Pfister D, Cooper MR, et al. Phase I studies of anti-epidermal growth factor receptor chimeric antibody C225 alone and in combination with cisplatin. J. Clin. Oncol. 18(4), 904-914 (2000) (Pubitemid 30106623)
14. Bonner JA, Harari PM, Giralt J, et al. Radiotherapy plus cetuximab for squamous cell carcinoma of the head and neck. N. Engl. J. Med. 354(6), 567-578 (2006) (Pubitemid 43209104)
15. Burtness B, Goldwasser MA, Flood W, Mattar B, Forastiere AA. Phase III randomized trial of cisplatin plus placebo compared with cisplatin plus cetuximab in metastatic/recurrent head and neck cancer: an Eastern Cooperative Oncology Group study. J. Clin. Oncol. 23(34), 8646-8654 (2005) (Pubitemid 46211507)
16. Vermorken JB, Trigo J, Hitt R, et al. Open-label, uncontrolled, multicenter Phase II study to evaluate the efficacy and toxicity of cetuximab as a single agent in patients with recurrent and/or metastatic squamous cell carcinoma of the head and neck who failed to respond to platinumbased therapy. J. Clin. Oncol. 25(16), 2171-2177 (2007) (Pubitemid 46954639)
17. Vermorken JB, Mesia R, Rivera F, et al. Platinum-based chemotherapy plus cetuximab in head and neck cancer. N. Engl. J. Med. 359, 1116-1127 (2008)
18. Milas L, Fan Z, Andratschke N, et al. Epidermal growth factor receptor and tumor response to radiation: in vivo preclinical studies. Int. J. Radiat. Oncol. Biol. Phys. 58, 966-971 (2004) (Pubitemid 38221157)
19. Bonner J, Harari P, Giralt J, et al. Radiotherapy plus cetuximab for locoregionally advanced head and neck cancer: 5-year survival data from a Phase 3 randomised trial, and relation between cetuximab-induced rash and survival. Lancet Oncol. 11, 21-27 (2010)
20. Kies MS, Harris J, Rotman MZ, et al. Phase II randomized trial of postoperative chemoradiation plus cetuximab for high-risk squamous cell carcinoma of the head and neck (RTOG 0234). Int. J. Radiat. Oncol. Biol. Phys. 75(3), S15 (2009)
21. Lefebvre JL. Surgery for laryngopharyngeal SCC in the era of organ preservation. Clin. Exp. Otorhinolaryngol. 2(4), 159-163 (2009)
22. Lefebvre JL, Pointreau Y, Rolland F, et al. Groupe Oncologie Radiotherapie Tete Et Cou (GORTEC). Sequential chemoradiotherapy (SCRT) for larynx preservation (LP), preliminary results of the randomized Phase II TREMPLIN study. Presented at: American Society of Clinical Oncology. Orlando, FL, USA, May-2 June 2009
23. Baselga J, Trigo JM, Bourhis J, et al. Phase II multicenter study of the antiepidermal growth factor receptor monoclonal antibody cetuximab in combination with platinum-based chemotherapy in patients with platinumrefractory metastatic and/or recurrent squamous cell carcinoma of the head and neck. J. Clin. Oncol. 23(24), 5568-5577 (2005)
24. Cohen EE, Kane MA, List MA, et al. Phase II trial of gefitinib 250 mg daily in patients with recurrent and/or metastatic squamous cell carcinoma of the head and neck. Clin. Cancer Res. 11(23), 8418-8424 (2005) (Pubitemid 41746956)
25. Stewart JS, Cohen E, Licitra L, et al. A Phase III randomized parallel-group study of gefitinib (IRESSA) versus methotrexate (IMEX) in patients with recurrent squamous cell carcinoma of the head and neck. Presented at: 98th Annual Meeting of the American Association for Cancer Research. Los Angeles, CA, USA, 14-18 April 2007
26. Wheeler RH, Jones D, Sharma P, et al. Clinical and molecular Phase II study of gefitinib in patients (pts) with recurrent squamous cell cancer of the head and neck (H&N Ca). J. Clin. Oncol. 23(16S), 507s (2005) (Abstract 5531)
27. Soulieres D, Senzer NN, Vokes EE, Hidalgo M, Agarwala SS, Siu LL. Multicenter Phase II study of erlotinib, an oral epidermal growth factor receptor tyrosine kinase inhibitor, in patients with recurrent or metastatic squamous cell cancer of the head and neck. J. Clin. Oncol. 22(1), 77-85 (2004) (Pubitemid 41095117)
28. Ezra E, Cohen W, Rosen F, et al. Phase II trial of ZD1839 in recurrent or metastatic squamous cell carcinoma of the head and neck. J. Clin. Oncol. 21(10), 1980-1987 (2003) (Pubitemid 46606387)
29. Argiris, Ghebremichael M, Gilbert J, Burtness B, Forastiere A. A Phase III randomized, placebo-controlled trial of docetaxel (D) with or without gefitinib (G) in recurrent or metastatic (R/M) squamous cell carcinoma of the head and neck (SCCHN), a trial of the Eastern Cooperative Oncology Group (ECOG). J. Clin. Oncol. 27 (15S), 6011 (2009)
30. Simon J, Stewart W, Vokes E, et al. Phase III study of gefitinib compared with intravenous methotrexate for recurrent squamous cell carcinoma of the head and neck. J. Clin. Oncol. 27, 1864-1871 (2009)
31. Pollack VA, Savage DM, Baker DA, et al. Inhibition of epidermal growth factor receptor-associated tyrosine phosphorylation in human carcinomas with CP-358, 774: dynamics of receptor inhibition in situ and antitumor effects in athymic mice. J. Pharmacol. Exp. Ther. 291, 739-748 (1999) (Pubitemid 29503548)
32. Hidalgo M, Siu LL, Nemunaitis J, et al. Phase I and pharmacologic study of OSI-774, an epidermal growth factor receptor tyrosine kinase inhibitor, in patients with advanced solid malignancies. J. Clin. Oncol. 19, 3267-3279 (2001) (Pubitemid 32591445)
33. Harrington K, El-Hariry I, Bourhis J, et al. Phase I study of lapatinib in combination with chemoradiation in patients with locally advanced squamous cell carcinoma of the head and neck. J. Clin. Oncol. 27(7), 1100-1107 (2009)
34. Ferrara N, Gerber HP. The role of vascular endothelial growth factor in angiogenesis. Acta Haematol. 106(4), 148-156 (2001) (Pubitemid 34124153)
35. Kies M, Gibson M, Kim S, et al. Cetuximab (C) and bevacizumab (B) in patients with recurrent or metastatic head and neck squamous cell carcinoma (SCCHN). An interim analysis. J. Clin. Oncol. 26(15S), 6072 (2008)
36. Feinstein T, Raez L, Rajasenan K, et al. Pemetrexed (P) and bevacizumab (B) in patients (pts) with recurrent or metastatic head and neck squamous cell carcinoma (HNSCC), updated results of a Phase II trial. J. Clin. Oncol. 26(15S), 6069 (2008)
37. Choong W, Cohen E, Kozloff M, et al. Phase II trial of sunitinib in patients with recurrent and/or metastatic squamous cell carcinoma of the head and neck (SCCHN). J. Clin. Oncol. 26(15S), 6064 (2008)
38. Loncaster JA, Cooper RA, Logue JP, et al. Vascular endothelial growth factor (VEGF) expression is a prognostic factor for radiotherapy outcome in advanced carcinoma of the cervix. Br. J. Cancer 83(5), 620-625 (2000) (Pubitemid 30636303)
39. Hockel M, Vaupel P. Biological consequences of tumor hypoxia. Semin. Oncol. 28(2 Suppl. 8), 36-41 (2001) (Pubitemid 32522236)
40. Gorski DH, Beckett MA, Jaskowiak NT, et al. Blockage of the vascular endothelial growth factor stress response increases the antitumor effects of ionizing radiation. Cancer Res. 59(14), 3374-3378 (1999) (Pubitemid 29334495)
41. Shemirani B, Crowe DL. Head and neck squamous cell carcinoma lines produce biologically active angiogenic factors. Oral Oncol. 36(1), 61-66 (2000)
42. Riedel F, Gotte K, Schwalb J, Wirtz H, Bergler W, Hormann K. Serum levels of vascular endothelial growth factor in patients with head and neck cancer. Eur. Arch. Otorhinolaryngol. 257(6), 332-336 (2000) (Pubitemid 30612326)
43. Smith BD, Smith GL, Carter D, Sasaki CT, Haffty BG. Prognostic significance of vascular endothelial growth factor protein levels in oral and oropharyngeal squamous cell carcinoma. J. Clin. Oncol. 18(10), 2046-2052 (2000) (Pubitemid 30324357)
44. Folkman J. What is the evidence that tumors are angiogenesis dependent? J. Natl Cancer Inst. 82(1), 4-6 (1990) (Pubitemid 20020880)
45. Wachsberger P, Burd R, Dicker AP. Tumor response to ionizing radiation combined with antiangiogenesis or vascular targeting agents: exploring mechanisms of interaction. Clin. Cancer Res. 9(6), 1957-1971 (2003) (Pubitemid 36687614)
46. Lothaire P, de Azambuja E, Dequanter D, et al. Molecular markers of head and neck squamous cell carcinoma: promising signs in need of prospective evaluation. Head Neck 28(3), 256-269 (2006) (Pubitemid 43269893)
47. O-Charoenrat P, Rhys-Evans P, Modjtahedi H, Eccles SA. Vascular endothelial growth factor family members aredifferentially regulated by c-ErbB signaling in head and neck squamous carcinoma cells. Clin. Exp. Metastasis 18(2), 155-161 (2000) (Pubitemid 32165249)
48. Vokes EE, Cohen EE, Mauer AM, et al. A Phase I study of erlotinib and bevacizumab for recurrent or metastatic squamous cell carcinoma of the head and neck (HNC). J. Clin. Oncol. 23(16S), 501s (2005) (Abstract 5504)
49. Cohen EE, Davis DW, Karrison TG, et al. Erlotinib and bevacizumab in patients with recurrent or metastatic squamous-cell carcinoma of the head and neck: a Phase I/II study. Lancet Oncol. 10(3), 204-205 (2009)
50. Feinstein T, Raez L, Rajasenan K, et al. Pemetrexed (P) and bevacizumab (B) in patients (pts) with recurrent or metastatic head and neck squamous cell carcinoma (HNSCC), updated results of a Phase II trial. J. Clin. Oncol. 26(15S), 6069 (2008)
51. Ceppi P, Volante M, Saviozzi S, et al. Squamous cell carcinoma of the lung compared with other histotypes shows higher messenger RNA and protein levels for thymidylate synthase. Cancer 107, 1589-1596 (2006) (Pubitemid 44546920)
52. Savvides P, Greskovich J, Bokar J, et al. Phase II study of bevacizumab in combination with docetaxel and radiation in locally advanced squamous cell cancer of the head and neck (SCCHN). J. Clin. Oncol. 25(18S), 302s (2007) (Abstract 6068)
53. Choong NW, Haraf DJ, Cohen EE, et al. Randomized Phase II study of concomitant chemoradiotherapy with 5-fluorouracil-hydroxyurea (FHX) compared to FHX and bevacizumab (FHXB) in intermediate stage head and neck cancer (HNC). J. Clin. Oncol. 25(18S), 302s (2007) (Abstract 6034)
54. Seiwert TY, Haraf DJ, Cohen E, et al. Phase I study of bevacizumab added to fluorouracil and hydroxyurea-based concomitant chemoradiotherapy for poor-prognosis head and neck cancer. J. Clin. Oncol. 26(10), 1732-1741 (2008)
55. Choong NW, Cohen EE, Kozloff MF, et al. Phase II trial of sunitinib in patients with recurrent and/or metastatic squamous cell carcinoma of the head and neck (SCCHN). J. Clin. Oncol. 26(15S), 332s (2008) (Abstract 6064)
56. Machiels H, Henry S, Zanetta S, et al. Phase II Study of sunitinib in recurrent or metastatic squamous cell carcinoma of the head and neck: GORTEC 2006-01. J. Clin. Oncol. 27(15S), 6024 (2009)
57. Saura C, Baselga J, Herbst R, et al. Antitumor activity of cediranib in patients with metastatic or recurrent head and neck cancer (HNC) or recurrent non-small cell lung cancer (NSCLC). An open-label exploratory study. J. Clin. Oncol. 27(15S), 6023 (2009)
58. Roccaro AM, Hideshima T, Richardson PG, et al. Bortezomib as an antitumor agent. Curr. Pharm. Biotechnol. 7(6), 441-448 (2006) (Pubitemid 46017535)
59. Milano A, Iaffaioli RV, Caponigro F. The proteasome: a worthwhile target for the treatment of solid tumours? Eur. J. Cancer 43(7), 1125-1133 (2007) (Pubitemid 46592015)
60. Scagliotti G. Proteasome inhibitors in the lung cancer. Crit. Rev. Oncol. Hematol. 58(3), 177-189 (2006)
61. Adams J. Development of the proteasome inhibitor PS-341. Oncologist 7, 9-16 (2002) (Pubitemid 34151104)
62. Lun M, Zhang PL, Pellitteri PK, Law A. Kennedy TL, Brown RE. Nuclear factor-kB pathway as a therapeutic target in head and neck squamous cell carcinoma: pharmaceutical and molecular validation in human cell lines using Velcade and siRNA/NFkB. Ann. Clin. Lab. Sci. 35, 251-258 (2005) (Pubitemid 41176783)
63. Van Waes C, Chang AA, Lebowitz PF, et al. Inhibition of nuclear factor-kB and target genes during combined therapy with proteasome inhibitor bortezomib and reirradiation in patients with recurrent head-and-neck squamous cell carcinoma. Int. J. Rad. Oncol. Biol. Phys. 63(5), 1400-1412 (2005) (Pubitemid 41628035)
64. Hayslip J, Chaudhary U, Green M, et al. Bortezomib in combination with celecoxib in patients with advanced solid tumors: a Phase I trial. BMC Cancer 7(221), 1-6 (2007)
65. Davies AM, Ho C, Metzger AS, et al. Phase I study of two different schedules of bortezomib and pemetrexed in advanced solid tumors with emphasis on non-small cell lung cancer. J. Thorac. Oncol. 2, 1112-1116 (2007) (Pubitemid 350307905)
66. Cohen SJ, Engstrom PF, Lewis NL, et al. Phase I study of capecitabine and oxaliplatin in combination with the proteasome inhibitor bortezomib in patients with advanced solid tumors. Am. J. Clin. Oncol. 31, 1-5 (2008)
67. Kubicek GJ, Machtay M, Axelrod RA, et al. Phase I trial of bortezomib (VELCADE), cisplatin and radiotherapy for advanced head and neck cancer. J. Clin. Oncol. 26(15 Suppl.), S323 (2008)
68. Lorch JH, Thomas TO, Schmoll HJ. Bortezomib inhibits cell-cell adhesion and cell migration and enhances epidermal growth factor receptor inhibitor-induced cell death in squamous cell cancer. Cancer Res. 67, 727-734 (2007) (Pubitemid 46192213)
69. Dudek AZ, Lesniewski-Kmak K, Shehadeh NJ, et al. Phase I study of bortezomib and cetuximab in patients with solid tumours expressing epidermal growth factor receptor. Br. J. Cancer 100, 1379-1384 (2009)
70. Chung CH, Aulino J, Muldowney NJ, et al. Nuclear factor-kB pathway and response in a Phase II trial of bortezomib and docetaxel in patients with recurrent and/or metastatic head and neck squamous cell carcinoma. Ann. Oncol. 21, 864-870 (2010)
71. Barnes CJ, Ohshiro K, Rayala SK, El-Naggar AK, Kumar R. Insulin-like growth factor receptor as a therapeutic target in head and neck cancer. Clin. Cancer Res. 13(14), 4291-4299 (2007) (Pubitemid 47105993)
72. Slomainy MG, Black LA, Kibbey MM, Tingler MA, Day TA, Rosenzweig SA. Insulin-like growth factor-1 receptor and ligand targeting in head and neck squamous cell carcinoma. Cancer Lett. 248(2), 269-279 (2007) (Pubitemid 46330562)
73. Abe S, Funato T, Takahashi S, et al. Increased expression of insulin-like growth factor 1 is associated with Ara-C resistance in leukemia. Tohoku J. Exp. Med. 209(3), 217-228 (2006) (Pubitemid 43905553)
74. Allen GW, Saba C, Armstrong EA, et al. Insulin-like growth factor-1 receptor signaling blockade combined with radiation. Cancer Res. 67(3), 1155-1162 (2007)
75. Desbois-Mouthon C, Cacheux W, Blivet-Van Eggelpoel MJ, et al. Impact of IGF-1R/EGFR cross-talks on hepatoma cell sensitivity of gefitinib. Int. J. Cancer 119(11), 2557-2566 (2006) (Pubitemid 44691308)
76. Knowlden JM, Hutchenson IR, Barrow, et al. Insulin-like growth factor-1 receptor signaling in tamoxifen-resistant breast cancer: a supporting role of the epidermal growth factor receptor. Endocrinology 146(11), 4609-4618 (2005) (Pubitemid 41446598)
77. Wan X, Helman LJ. Effect of insulin-like growth factor II on protecting myoblast cells against cisplatin-induced apoptosis through p70 S6 kinase pathway. Neoplasia 4(5), 400-408 (2002) (Pubitemid 34976955)
78. Yin D, Tamaki N, Parent AD, et al. Insulinlike growth factor-1 decreased etoposideinduced apoptosis in glioma cells by increasing bcl-2 expression and decreasing CPP32 activity. Neurol. Res. 27(1), 27-35 (2005) (Pubitemid 40189601)
79. Lacy MQ, Alsina M, Fonseca R, et al. Phase I, pharmacokinetic and pharmacodynamic study of the anti-insulin like growth factor type 1 receptor monoclonal antibody CP-751871 in patients with multiple myeloma. J. Clin. Oncol. 26(19), 3196-3203 (2008)
80. Haluska P, Shaw HM, Batzel GN, et al. Phase I dose escalation study of the anti insulin-like growth factor-1 receptor monoclonal antibody CP-751, 871 in patients with refractory solid tumors. Clin. Cancer Res. 13(19), 5834-5840 (2007) (Pubitemid 47583908)
81. Karp DD, Paz-Ares LG, Blakely LJ, et al. Efficacy of the anti-insulin like growth factor 1 receptor antibody CP-751871 in combination with paclitaxel and carboplatin as first line treatment for advanced non-small cell lung cancer (NSCLC). J. Clin. Oncol. 25(18S), 7506 (2007)
82. Karp DD, Novello S, Cardenal F, et al. Continued high activity of figitumumab (CP-751, 871) combination therapy in squamous lung cancer. J. Clin. Oncol. 27(15S) (2009)
83. Postel-Vinay S, Okuno S, Schuetze S, et al. Safety, pharmacokinetics and preliminary activity of the anti-IGF-1R antibody CP-751, 871 in patients with sarcoma. Proc. Eur. J. Cancer 6(12), 388 (2008)
84. Higano CS, Yu EY, Whiting SH, et al. A Phase I, first in man study of weekly IMC-A12, a fully human insulin like growth factor-1 receptor IgG1 monoclonal antibody, in patients with advanced solid tumors. J. Clin. Oncol. 25(18S), 3505 (2007)
85. Rothenberg ML. Phase I dose-escalation study of the anti-IGF-1R recombinant human IgG1 monoclonal antibody (Mab) IMC-A12, administered every other week to patients with advanced solid tumors. Mol. Target Cancer Ther. 12, 84 (2007)
86. Tolcher AW, Rothenberg ML, Rodon J, et al. A Phase I pharmacokinetic and pharmacodynamic study of AMG-479, a fully human monoclonal antibody against insulin-like growth factor type 1 receptor (IGF-1R), in advanced solid tumors. J. Clin. Oncol. 25(18S), 3002 (2007)
87. Sarantopoulus J, Mita AC, Mulay M, et al. A Phase IB study of AMG-479, a type 1 insulin-like growth factor receptor (IGF-1R) antibody, in combination with panitumumab (P) or gemcitabine (G). J. Clin. Oncol. 26(15S), 3583 (2008)
88. Clayman GL, Frank DK, Bruso PA, Goepfert H. Adenovirus-mediated wild-type p53 gene transfer as a surgicaladjuvant in head and neck cancers. Clin. Cancer Res. 5, 1715-1722 (1999) (Pubitemid 29334451)
89. Clayman GL, El-Naggar AK, Lippman SM, et al. Adenovirus-mediated p53 gene transfer in patients with advanced recurrent head and neck squamous cell carcinoma. J. Clin. Oncol. 16, 2221-2232 (1998) (Pubitemid 28265061)
90. Nemunaitis J, Hamm J, Clayman GL, et al. Tumor response and biomarkers associated with increased survival following adenoviral p53 gene therapy (ADVEXIN) in patients with recurrent squamous cell carcinoma of the head and neck. J. Clin. Oncol. 25(18S), 313 (2007) (Abstract 6057)
91. Goodwin WJ, Esser D, Clayman GL, Nemunaitis J, Yver A. Dreiling L. Randomized Phase II study of intratumoral injections of two dosing schedules using a replication-deficient adenovirus carrying p53 gene (Ad5CMV-p53) in patients with recurrent/refractory head and neck cancer. Proc. Am. Soc. Clin. Oncol. 18, 445a (1999) (Abstract 1717)
92. Bier-Laning CM, VanEcho D, Yver A. A Phase II multi-center study of AdCMV-p53 administered intratumorally to patients with recurrent head and neck cancer. Proc. Am. Soc. Clin. Oncol. 18, 431a (1999) (Abstract 1712)
93. Yoo GH, Moon J, LeBlanc M, et al. A Phase II trail of surgery with perioperative INGN 201 (Ad5CMV-p53) gene therapy followed by chemoradiotherapy for advanced, resectable squamous cell carcinoma of the oral cavity, oropharynx, hypopharynx, and larynx. Report of the Southwest oncology group. Arch. Otolaryngol. Head Neck Surg. 135(9), 869-874 (2009)
94. Ganly I, Kirn D, Eckhardt SG, et al. A Phase I study of Onyx-015, an E1B attenuated adenovirus, administered intratumorally to patients with recurrent head and neck cancer. Clin. Cancer Res. 6, 798-806 (2000) (Pubitemid 30159332)
95. Nemunaitis J, Ganly I, Khuri F, et al. Selective replication and oncolysis in p53 mutant tumors with Onyx-015, an E1B55Kd gene-deleted adenovirus, in patients with advanced head and neck cancer: a Phase II trial. Cancer Res. 60, 6359-6366 (2000)
96. Bischoff JR. An adenovirus mutant that replicates selectively in p53-deficient tumor cells. Science 274, 373-376 (1996) (Pubitemid 26353341)
97. Khuri FR, Nemunaitis J, Ganly I, et al. A controlled trial of intratumoral Onyx-015, a selectively-replicating adenovirus, in combination with cisplatin and 5-FU in patients with recurrent head and neck cancer. Nat. Med. 6(8), 879-885 (2000) (Pubitemid 30644745)
98. Gillison ML, Harris J, Westra W, et al. Survival outcomes by tumor human papillomavirus (HPV) status in stage III-IV oropharyngeal cancer (OPC) in RTOG 0129. J. Clin. Oncol. 27(15 Suppl.) (2009) (Abstract 6003)
99. Perrone F, Bossi P, Cortelazzi B, et al. TP53 mutations and pathologic complete response to neoadjuvant cisplatin and fluorouracil chemotherapy in resected oral cavity squamous cell carcinoma. J. Clin. Oncol. 28(5), 761-766 (2010)
100. Holgersson G, Ekman S, Reizenstein J, et al. Molecular profiling using tissue microarrays as a tool to identify predictive biomarkers in laryngeal cancer treated with radiotherapy. Cancer Genomics Proteomics 7(1), 1-7 (2010)
101. Silva P, Slevin NJ, Sloan P, et al. Use of multiple biological markers in radiotherapy-treated head and neck cancer. J. Laryngol. Otol. 14, 1-9 (2010)
102. Lajer CB, von Buchwald C. The role of human papillomavirus in head and neck cancer. APMIS 118(6-7), 510-519 (2010)
103. Clinicaltrials.gov http://clinicaltrials.gov/ct2/results?term=NCT00412217 (Accessed 24 February 2011)